ClinicalTrials.gov
ClinicalTrials.gov Menu

TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00255099
Recruitment Status : Completed
First Posted : November 17, 2005
Last Update Posted : June 15, 2011
Sponsor:
Information provided by:
Tibotec Pharmaceuticals, Ireland

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : January 2007
  Actual Study Completion Date : July 2008
  Certification/Extension First Submitted : June 2, 2011
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):